Citius Oncology, Inc.
CTOR
Rank in Stocks
#22649
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Share Price
$0.5495
Last synced: 2026-11-09
Market Cap
$51.09M
Change (1 day)
7.85%
Change (1 year)
-59.89%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Citius Oncology, Inc. (CTOR)
Category
Healthcare
EPS for Citius Oncology, Inc. (CTOR)
EPS as of June 2026 TTM: $-0.48
According to Citius Oncology, Inc.'s latest financial reports, its current EPS (TTM) is $-0.48. At the end of 2025 the company had an EPS of $-0.34, a decrease compared to its 2024 EPS of $-0.30.
EPS history for Citius Oncology, Inc. from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.48 | 41.18% |
| 2025 | $-0.34 | 13.33% |
| 2024 | $-0.30 | 57.89% |
| 2023 | $-0.19 | 149.02% |
| 2022 | $-0.08 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.89 | -6,535.42% |
US
|
|
| $6.60 | -1,475.00% |
US
|
|
| $5.83 | -1,314.58% |
US
|
|
| $0.98 | -304.17% |
US
|
|
| $18.54 | -3,962.92% |
CH
|
Questions about Citius Oncology, Inc.'s earnings per share (EPS)
What is Citius Oncology, Inc.'s earnings per share (EPS)?
Citius Oncology, Inc.'s earnings per share (EPS) over the last twelve months is $-0.48, as of Jun 2026.
What was Citius Oncology, Inc.'s earnings per share (EPS) in 2025?
In 2025, Citius Oncology, Inc.'s earnings per share (EPS) was $-0.34, compared with $-0.30 in 2024.
How has Citius Oncology, Inc.'s earnings per share (EPS) changed since 2022?
From 2022 to 2025, Citius Oncology, Inc.'s earnings per share (EPS) was highest in 2022 ($-0.08) and lowest in 2025 ($-0.34).
How does Citius Oncology, Inc.'s earnings per share (EPS) compare with similar companies?
Citius Oncology, Inc.'s earnings per share (EPS) ($-0.48) is lower than that of all 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.